Valuation: Royalty Pharma plc

Market Cap 25.02B 21.87B 20.21B 18.68B 35.17B 2,404B 35.81B 241B 94.58B 1,177B 93.99B 91.91B 4,052B P/E 2026 *
21.3x
P/E 2027 * 14.9x
Enterprise Value 34.18B 29.87B 27.61B 25.51B 48.04B 3,283B 48.91B 329B 129B 1,607B 128B 126B 5,535B EV / Sales 2026 *
9.88x
EV / Sales 2027 * 9.32x
Free-Float
71.97%
Yield 2026 *
1.77%
Yield 2027 * 1.85%
1 day-1.11%
1 week-3.44%
Current month-0.46%
1 month+2.84%
3 months+14.32%
6 months+38.80%
Current year+44.44%
1 week 55.62
Extreme 55.62
58.84
1 month 51.15
Extreme 51.15
58.84
Current year 38.29
Extreme 38.29
58.84
1 year 34.08
Extreme 34.0805
58.84
3 years 24.05
Extreme 24.05
58.84
5 years 24.05
Extreme 24.05
58.84
10 years 24.05
Extreme 24.05
58.84
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Executive/Senior Manager

-9,099 0.0021%
06-29Sell

Executive/Senior Manager

-130,000 0.0293%
06-29Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-3.44%+54.00%+81.61% 25.02B
-2.07%-6.65%+44.29%+156.61% 1,054B
-1.80%-5.36%+61.27%+58.20% 621B
-1.18%-3.91%+27.77%+79.91% 438B
-1.12%-3.68%+26.89%+20.58% 325B
-1.73%-3.45%+26.95%+44.09% 281B
-1.95%-13.92%+15.96%+19.76% 262B
-1.45%-2.37%-27.87%-39.87% 219B
-1.25%-3.38%+19.74%+56.39% 195B
-0.62%-4.50%+16.18%+68.71% 163B
Average -1.47%-1.61%+26.52%+54.60% 358.12B
Weighted average by Cap. -1.67%-1.68%+33.25%+77.04%

Financials

2026 *2027 *
Net sales 3.46B 3.02B 2.8B 2.58B 4.86B 332B 4.95B 33.34B 13.08B 163B 13B 12.71B 560B 3.69B 3.22B 2.98B 2.75B 5.18B 354B 5.27B 35.51B 13.93B 173B 13.84B 13.54B 597B
Net income 1.65B 1.45B 1.34B 1.23B 2.32B 159B 2.37B 15.93B 6.25B 77.79B 6.21B 6.08B 268B 2.24B 1.95B 1.81B 1.67B 3.14B 215B 3.2B 21.55B 8.46B 105B 8.4B 8.22B 362B
Net Debt 9.15B 8B 7.39B 6.83B 12.87B 879B 13.1B 88.18B 34.6B 431B 34.38B 33.62B 1,482B 9.33B 8.15B 7.53B 6.96B 13.11B 896B 13.34B 89.84B 35.25B 439B 35.03B 34.25B 1,510B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-14 US$55.78 -1.19% 717,074
26-07-13 US$56.45 +0.04% 2,217,147
26-07-10 US$56.43 -2.64% 2,518,730
26-07-09 US$57.96 -0.70% 3,322,552
26-07-08 US$58.37 +0.99% 3,281,287
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
56.45USD
Average target price
59.89USD
Spread / Average Target
+6.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock